Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer

BACKGROUND: Everolimus is a mTOR inhibitor used for the treatment of different solid malignancies. Many patients treated with the registered fixed 10 mg dose once daily are in need of dose interruptions, reductions or treatment discontinuation due to severe adverse events. This study determined the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Chemother Pharmacol
Huvudupphovsmän: de Wit, D., Schneider, T. C., Moes, D. J. A. R., Roozen, C. F. M., den Hartigh, J., Gelderblom, H., Guchelaar, H. J., van der Hoeven, J. J., Links, T. P., Kapiteijn, E., van Erp, N. P.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Berlin Heidelberg 2016
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4921118/
https://ncbi.nlm.nih.gov/pubmed/27169792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3050-6
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk